2019.12
Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer
The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations
